“Ibalizumab was approved with 40 patients and 43% efficacy in 25 weeks study IV Infusion ..with some side effects ..
one or two years ago.”
True, but ibalizumab had already completed a phase 2 with 113 patients AND had a concurrent phase 3 with another 78 patients. Additionally, the ibalizumab phase 3 study was published in the NJEM.
Full data from the combo trial, CD02, has never been released, which it should have been by now considering the trial completed in 2018.